X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs IPCA LABS - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER IPCA LABS PFIZER/
IPCA LABS
 
P/E (TTM) x 32.8 36.4 90.2% View Chart
P/BV x 4.9 3.5 141.4% View Chart
Dividend Yield % 0.8 0.1 520.5%  

Financials

 PFIZER   IPCA LABS
EQUITY SHARE DATA
    PFIZER
Mar-17
IPCA LABS
Mar-17
PFIZER/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs2,055643 319.6%   
Low Rs1,651503 328.4%   
Sales per share (Unadj.) Rs429.8254.4 168.9%  
Earnings per share (Unadj.) Rs73.616.1 458.1%  
Cash flow per share (Unadj.) Rs87.429.8 293.4%  
Dividends per share (Unadj.) Rs20.001.00 2,000.0%  
Dividend yield (eoy) %1.10.2 618.3%  
Book value per share (Unadj.) Rs528.7194.6 271.8%  
Shares outstanding (eoy) m45.75126.20 36.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.32.3 191.5%   
Avg P/E ratio x25.235.7 70.6%  
P/CF ratio (eoy) x21.219.2 110.2%  
Price / Book Value ratio x3.52.9 119.0%  
Dividend payout %27.26.2 436.6%   
Avg Mkt Cap Rs m84,77772,300 117.3%   
No. of employees `0002.813.3 21.3%   
Total wages/salary Rs m3,0396,960 43.7%   
Avg. sales/employee Rs Th6,925.92,413.5 287.0%   
Avg. wages/employee Rs Th1,070.4523.2 204.6%   
Avg. net profit/employee Rs Th1,186.3152.4 778.1%   
INCOME DATA
Net Sales Rs m19,66332,106 61.2%  
Other income Rs m1,012226 448.2%   
Total revenues Rs m20,67432,332 63.9%   
Gross profit Rs m3,4914,448 78.5%  
Depreciation Rs m6291,730 36.4%   
Interest Rs m10241 4.0%   
Profit before tax Rs m3,8642,703 142.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,3040-   
Tax Rs m1,801675 266.7%   
Profit after tax Rs m3,3682,028 166.1%  
Gross profit margin %17.813.9 128.2%  
Effective tax rate %46.625.0 186.6%   
Net profit margin %17.16.3 271.2%  
BALANCE SHEET DATA
Current assets Rs m20,78917,340 119.9%   
Current liabilities Rs m7,8709,559 82.3%   
Net working cap to sales %65.724.2 271.1%  
Current ratio x2.61.8 145.6%  
Inventory Days Days60100 59.6%  
Debtors Days Days2257 39.4%  
Net fixed assets Rs m9,17520,779 44.2%   
Share capital Rs m458252 181.3%   
"Free" reserves Rs m23,73124,499 96.9%   
Net worth Rs m24,18924,553 98.5%   
Long term debt Rs m253,517 0.7%   
Total assets Rs m32,70639,595 82.6%  
Interest coverage x403.512.2 3,300.4%   
Debt to equity ratio x00.1 0.7%  
Sales to assets ratio x0.60.8 74.1%   
Return on assets %10.35.7 180.2%  
Return on equity %13.98.3 168.6%  
Return on capital %21.410.5 203.9%  
Exports to sales %048.6 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA15,617 0.0%   
Imports (cif) Rs mNA4,571 0.0%   
Fx inflow Rs m6315,617 0.4%   
Fx outflow Rs m4,0675,828 69.8%   
Net fx Rs m-4,0049,790 -40.9%   
CASH FLOW
From Operations Rs m3,2882,764 118.9%  
From Investments Rs m-2,496-1,432 174.4%  
From Financial Activity Rs m-826-1,591 51.9%  
Net Cashflow Rs m-35-259 13.4%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 11.4 65.8%  
FIIs % 4.9 25.3 19.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.4 136.2%  
Shareholders   85,207 36,892 231.0%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  NATCO PHARMA  AUROBINDO PHARMA  SANOFI INDIA  

Compare PFIZER With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jun 21, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS